Safe Stopping of Tocilizumab in RA: MTX Helps Safe Stopping of Tocilizumab in RA: MTX Helps

Patients with rheumatoid arthritis who achieve 6 months of remission or low disease activity by taking methotrexate plus tocilizumab can usually stop tocilizumab; restarting is effective if flares occur.Medscape Medical News
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Rheumatology News Source Type: news

Related Links:

Authors: Tian S, Yan Y, Qi X, Li X, Li Z Abstract BACKGROUND Rheumatoid arthritis model (CIA) rats were treated by tail vein injection of IL-10-modified bone marrow mesenchymal stem cells (BMSCs) to investigate its feasibility and intrinsic molecular mechanism. MATERIAL AND METHODS The CIA rat model was established by induction type II collagen, and IL-10-modified BMSCs was established by transfecting BMSCs with adenovirus. IL-10-modified BMSCs were used to treat the CIA rats. The therapeutic effect was evaluated by measuring the changes in body weight, ankle swelling, and forced swimming time, as well as observati...
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
The Monarch external Trigeminal Nerve Stimulation (eTNS) System made history last week after it became the first device to win a nod from FDA to treat attention deficit hyperactivity disorder (ADHD). It should be noted the technology has had CE mark since 2015. Monarch was developed by NeuroSigma and is indicated to help treat 7 to 12-year-olds suffering from ADHD. What makes this de novo clearance from FDA so significant is that typically pharmaceutical solutions are used to treat patients suffering from the neurological disorder. Monarch is about the size of a cellphone. The device generates a low-level electrical pulse ...
Source: MDDI - Category: Medical Devices Authors: Tags: Digital Health Source Type: news
AbstractAdvanced imaging has become just as vital for diagnosing, staging, and monitoring disease in rheumatoid arthritis (RA) patients as it is for cancer patients. Part 1 of this review discussed synovitis, tenosynovitis, erosions, and osteitis —key imaging findings that occur in patients with RA. Part 2 will now show how these features, in combination with clinical and serologic data, can assist clinical decision-making at various stages of a patient’s disease course. Specifically, assessing current disease activity and prognosticatin g future aggressiveness inform treatment decisions at initial presentation...
Source: Skeletal Radiology - Category: Radiology Source Type: research
Journal of Interferon&Cytokine Research, Ahead of Print.
Source: Journal of Interferon and Cytokine Research - Category: Molecular Biology Authors: Source Type: research
ConclusionThe present study indicated that the identified DEGs and hub genes promote our understanding of molecular mechanisms underlying the development of RA, such as C-C motif chemokine 5 (CCL5), might have a negative impact in the development of RA. CCL5 and its related genes might be the potential diagnostic biomarkers for the therapeutic strategies of RA.
Source: Clinical Rheumatology - Category: Rheumatology Source Type: research
Journal of Interferon&Cytokine Research, Ahead of Print.
Source: Journal of Interferon - Category: Research Authors: Source Type: research
m Kim Rheumatoid arthritis (RA) is a chronic, systemic, joint-invading, autoimmune inflammatory disease, which causes joint cartilage breakdown and bone damage, resulting in functional impairment and deformation of the joints. The percentage of RA patients has been rising and RA represents a substantial burden for patients around the world. Despite the development of many RA therapies, because of the side effects and low effectiveness of conventional drugs, patients still need and researchers are seeking new therapeutic alternatives. Polyphenols extracted from natural products are effective on several inflammatory ...
Source: Molecules - Category: Chemistry Authors: Tags: Review Source Type: research
CONCLUSIONS: Abatacept inhibits FLS migration and MMPs expressions via inhibiting MAPK pathway, thereby inhibiting RA development. PMID: 31002160 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
Authors: De Simone C, Caldarola G, Moretta G, Piscitelli L, Ricceri F, Prignano F Abstract Psoriasis affects 2-4% of the world's population, with no difference between men and women and 70% of patients experiencing disease onset before the age of 40, which coincides with the reproductive years. Few data are available from literature on impact of psoriasis on fertility, course and outcome of pregnancy and risk associated with treatments. Recent studies on other immune-mediated inflammatory diseases, among which psoriasis is also included, indicate that rheumatoid arthritis and inflammatory bowel diseases can impact ...
Source: Giornale Italiano di Dermatologia e Venereologia - Category: Dermatology Tags: G Ital Dermatol Venereol Source Type: research
Conclusions: The antirheumatic effects of SM were associated with the regulation of the ATX-LPA and MAPK pathways, the suppression of proinflammatory cytokine production, and the alleviation of cartilage and bone injury. These findings suggest that SM might be a promising alternative candidate for RA therapy. PMID: 31001354 [PubMed]
Source: Evidence-based Complementary and Alternative Medicine - Category: Complementary Medicine Tags: Evid Based Complement Alternat Med Source Type: research
More News: Actemra | Arthritis | Health | Methotrexate | Rheumatoid Arthritis | Rheumatology